28272842|t|Improved risk stratification for patients with high-grade urothelial carcinoma following application of the Paris System for Reporting Urinary Cytology
28272842|a|The Paris System for Reporting Urinary Cytology (TPS) requires 4 cytomorphologic criteria for a definitive diagnosis of high-grade urothelial carcinoma (HGUC) in urinary tract cytology (UTC) specimens: an elevated nuclear-to-cytoplasmic (N/C) ratio (at or above 0.7), markedly atypical nuclear borders, moderate to severe hyperchromasia, and coarse chromatin. However, malignant UTC specimens often contain degenerative changes, and this limits the number of malignant cells meeting all 4 TPS cytomorphologic criteria. One hundred twelve UTC specimens from patients with a subsequent diagnosis of HGUC were reviewed and reclassified according to TPS criteria. The presence of TPS cytomorphologic criteria for HGUC in each specimen was recorded, as was the proportion of atypical cells meeting all 4 criteria. The number of specimens definitively diagnosed as HGUC did not significantly change upon reclassification. However, approximately 40% of indeterminate specimens (21 of 51) were reclassified into a higher risk category. The most restrictive cytomorphologic criterion was an N/C ratio of 0.7 or higher (seen in 78% of specimens), and approximately half of specimens containing all 4 cytomorphologic criteria did not meet TPS 's numerical criterion for HGUC (at least 5 malignant cells). In the majority of specimens qualifying for HGUC by TPS standards, only a small fraction of atypical cells (10%-20%) met all the criteria. When applied to malignant UTC specimens, TPS criteria improved specimen risk stratification by upgrading approximately 40% of indeterminate specimens into higher risk categories while not significantly changing the frequency of HGUC diagnoses. Cancer Cytopathol 2017. Â© 2017 American Cancer Society.
28272842	0	8	Improved	T033	C0184511
28272842	9	13	risk	T078	C0035647
28272842	14	28	stratification	T062	C1514983
28272842	33	41	patients	T101	C0030705
28272842	58	78	urothelial carcinoma	T191	C2145472
28272842	108	113	Paris	T083	C0030561
28272842	114	120	System	T169	C0449913
28272842	125	134	Reporting	T058	C0700287
28272842	135	151	Urinary Cytology	T059	C2979983
28272842	156	161	Paris	T083	C0030561
28272842	162	168	System	T169	C0449913
28272842	173	182	Reporting	T058	C0700287
28272842	183	199	Urinary Cytology	T059	C2979983
28272842	201	204	TPS	T059	C2979983
28272842	217	232	cytomorphologic	T026	C0243092
28272842	233	241	criteria	T078	C0243161
28272842	259	268	diagnosis	T033	C0011900
28272842	272	303	high-grade urothelial carcinoma	T191	C2145472
28272842	305	309	HGUC	T191	C2145472
28272842	314	336	urinary tract cytology	T059	C2979983
28272842	338	341	UTC	T059	C2979983
28272842	343	352	specimens	T167	C0370003
28272842	357	365	elevated	T080	C3163633
28272842	366	400	nuclear-to-cytoplasmic (N/C) ratio	T049	C0333907
28272842	429	437	atypical	T080	C0205182
28272842	438	445	nuclear	T026	C0007610
28272842	446	453	borders	T082	C0205284
28272842	455	463	moderate	T080	C0205081
28272842	467	473	severe	T080	C0205082
28272842	474	488	hyperchromasia	T033	C0333910
28272842	494	510	coarse chromatin	T033	C1868540
28272842	521	530	malignant	T080	C0205282
28272842	531	534	UTC	T059	C2979983
28272842	535	544	specimens	T167	C0370003
28272842	559	571	degenerative	T169	C1880269
28272842	572	579	changes	T169	C0392747
28272842	611	626	malignant cells	T025	C0334227
28272842	641	644	TPS	T059	C2979983
28272842	645	660	cytomorphologic	T026	C0243092
28272842	661	669	criteria	T078	C0243161
28272842	690	693	UTC	T059	C2979983
28272842	694	703	specimens	T167	C0370003
28272842	709	717	patients	T101	C0030705
28272842	736	745	diagnosis	T033	C0011900
28272842	749	753	HGUC	T191	C2145472
28272842	759	767	reviewed	T080	C1709940
28272842	772	784	reclassified	T080	C0205542
28272842	798	801	TPS	T059	C2979983
28272842	802	810	criteria	T078	C0243161
28272842	816	824	presence	T033	C0150312
28272842	828	831	TPS	T059	C2979983
28272842	832	847	cytomorphologic	T026	C0243092
28272842	848	856	criteria	T078	C0243161
28272842	861	865	HGUC	T191	C2145472
28272842	874	882	specimen	T167	C0370003
28272842	922	930	atypical	T080	C0205182
28272842	931	936	cells	T025	C0007634
28272842	951	959	criteria	T078	C0243161
28272842	975	984	specimens	T167	C0370003
28272842	998	1007	diagnosed	T033	C0011900
28272842	1011	1015	HGUC	T191	C2145472
28272842	1024	1037	significantly	T078	C0750502
28272842	1038	1044	change	T169	C0392747
28272842	1050	1066	reclassification	T185	C0008902
28272842	1077	1090	approximately	T080	C0332232
28272842	1098	1111	indeterminate	T078	C0205258
28272842	1112	1121	specimens	T167	C0370003
28272842	1138	1150	reclassified	T080	C0205542
28272842	1165	1169	risk	T078	C0035647
28272842	1170	1178	category	T170	C0683312
28272842	1201	1216	cytomorphologic	T026	C0243092
28272842	1234	1243	N/C ratio	T049	C0333907
28272842	1277	1286	specimens	T167	C0370003
28272842	1293	1306	approximately	T080	C0332232
28272842	1315	1324	specimens	T167	C0370003
28272842	1315	1324	specimens	T167	C0370003
28272842	1342	1357	cytomorphologic	T026	C0243092
28272842	1358	1366	criteria	T078	C0243161
28272842	1380	1383	TPS	T059	C2979983
28272842	1411	1415	HGUC	T191	C2145472
28272842	1428	1443	malignant cells	T025	C0334227
28272842	1465	1474	specimens	T167	C0370003
28272842	1490	1494	HGUC	T191	C2145472
28272842	1498	1501	TPS	T059	C2979983
28272842	1526	1537	fraction of	T081	C1264633
28272842	1538	1546	atypical	T080	C0205182
28272842	1547	1552	cells	T025	C0007634
28272842	1575	1583	criteria	T078	C0243161
28272842	1601	1610	malignant	T080	C0205282
28272842	1611	1614	UTC	T059	C2979983
28272842	1615	1624	specimens	T167	C0370003
28272842	1626	1629	TPS	T059	C2979983
28272842	1630	1638	criteria	T078	C0243161
28272842	1639	1647	improved	T033	C0184511
28272842	1648	1656	specimen	T167	C0370003
28272842	1657	1661	risk	T078	C0035647
28272842	1662	1676	stratification	T062	C1514983
28272842	1690	1703	approximately	T080	C0332232
28272842	1711	1724	indeterminate	T078	C0205258
28272842	1725	1734	specimens	T167	C0370003
28272842	1747	1751	risk	T078	C0035647
28272842	1752	1762	categories	T170	C0683312
28272842	1773	1786	significantly	T078	C0750502
28272842	1787	1795	changing	T169	C0392747
28272842	1800	1809	frequency	T079	C0376249
28272842	1813	1817	HGUC	T191	C2145472
28272842	1818	1827	diagnoses	T033	C0011900
28272842	1829	1835	Cancer	T191	C0006826
28272842	1860	1883	American Cancer Society	T094	C0002455